A
The startup is developing a novel class of small immunotherapies that target specific cancer cell pathways to enhance the immune response against tumors. This approach aims to improve treatment efficacy while minimizing side effects associated with traditional cancer therapies.
Menlo Park, United States
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup is developing a novel class of small immunotherapies that target specific cancer cell pathways to enhance the immune response against tumors. This approach aims to improve treatment efficacy while minimizing side effects associated with traditional cancer therapies.